Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 11/20 | 0.75 |
| ▸ | FNTB | P49356 | 8/20 | 0.75 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.75 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7620103 | 1.00 | FNTA (0.75) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL6550660 | 0.86 | FNTA (1.00) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL7628849 | 0.86 | FNTA (1.00) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL7628855 | 0.86 | FNTA (1.00) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL6550666 | 0.86 | FNTA (1.00) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL6551951 | 0.81 | FNTA (0.73) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL6551971 | 0.80 | FNTA (0.69) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL6550485 | 0.79 | FNTA (1.00) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL8940790 | 0.79 | FNTA (1.00) | FNTAFNTBPGGT1BTRPV1TRPA1 | |
| SCHEMBL6550494 | 0.79 | FNTA (1.00) | FNTAFNTBPGGT1BTRPV1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | CAMPOCHIARO PETER A (US) | 2002-01-17 | — | — | US | disclosed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5362906-A | Antitumor | MERCK & CO., INC. (US) | 1994-11-08 | — | — | US | disclosed |
| US-5298655-A | Enzyme inhibitors or anticarcinogenic agents | MERCK & CO., INC. (US) | 1994-03-29 | — | — | US | disclosed |
| EP-0534546-A1 | Farnesyl pyrophosphate analogs | MERCK & CO. INC. (US) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | GGT1, FNTA, PIGO | FNTA 2/4885FNTB 11/4885PGGT1B 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.